Muscle Growth$30–$59

Ipamorelin: Dosage, Benefits & Side Effects

By Peptide Assistant Editorial Team · · · 9 sources cited

Overview

Ipamorelin is a selective growth hormone secretagogue pentapeptide that stimulates GH release with remarkable specificity — it activates the ghrelin receptor without significantly affecting cortisol or prolactin in animal studies. This selectivity profile makes it the 'cleanest' GHRP and the most widely used growth hormone peptide for anti-aging, body composition, sleep enhancement, and recovery. Developed by Novo Nordisk in the 1990s, it has become the foundational GH peptide in clinical and self-directed protocols worldwide.

Mechanism of Action

Ipamorelin selectively activates the growth hormone secretagogue receptor type 1a (GHS-R1a) on somatotroph cells in the anterior pituitary gland. Upon receptor binding, it triggers phospholipase C activation, IP3-mediated calcium release from the endoplasmic reticulum, and subsequent GH vesicle exocytosis — producing a pulsatile GH release that closely mimics the body's natural secretion pattern. What distinguishes Ipamorelin from other GHRPs is its extraordinary selectivity. While GHRP-2, GHRP-6, and hexarelin also bind GHS-R1a, they produce dose-dependent increases in ACTH, cortisol, and prolactin due to off-target receptor interactions. Ipamorelin left ACTH and cortisol unchanged at doses more than 200-fold above the ED50 for GH release. This selectivity was demonstrated in rats and swine by Raun et al. (1998); it has not been tested over long-term use in people. Ipamorelin also has minimal appetite-stimulating effects compared to GHRP-6, as it does not significantly activate the hypothalamic hunger circuits driven by ghrelin receptor agonism in the arcuate nucleus. In human volunteers its pharmacokinetics were dose-proportional and each dose produced a single episode of GH release, with half-maximal GH stimulation at a plasma concentration of 214 nmol/l and a ceiling on the GH production rate. Importantly, Ipamorelin's GH release is still subject to somatostatin-mediated negative feedback — meaning it will not cause supraphysiological GH levels under normal conditions. This physiological 'ceiling' is a key safety feature. When combined with GHRH analogs (such as CJC-1295), a synergistic amplification occurs: GHRH primes the somatotrophs while Ipamorelin triggers release and antagonizes somatostatin, producing GH release greater than either peptide alone. This GHRH+GHRP combination is considered the gold standard for GH optimization. Beyond direct GH effects, the elevated GH from Ipamorelin stimulates hepatic IGF-1 production, which mediates many of the downstream anabolic, tissue-repair, and metabolic benefits. Increased GH also enhances lipolysis (fat burning) through hormone-sensitive lipase activation, improves protein synthesis rates, and promotes deep slow-wave sleep — the restorative sleep phase during which GH secretion naturally peaks.

Ipamorelin Benefits: What the Research Shows

  • Raun et al. (1998) published the defining study in the European Journal of Endocrinology demonstrating Ipamorelin's selectivity in rats and swine — GH release was dose-dependent while ACTH, cortisol, prolactin and FSH/LH stayed at baseline, even at doses over 200 times the ED50
  • In adult female rats, 12 weeks of continuous ipamorelin increased bone mineral content measured by DXA, although volumetric bone mineral density was unchanged (Svensson et al., 2000, Journal of Endocrinology)
  • In a phase 2 trial in bowel resection patients (Beck et al., 2014, International Journal of Colorectal Disease), intravenous ipamorelin shortened median time to first tolerated meal from 32.6 to 25.3 hours, a difference that was not statistically significant
  • In rats, 15 days of ipamorelin dose-dependently increased longitudinal bone growth and body weight gain without changing total IGF-I levels
  • Studies demonstrate that Ipamorelin's GH release is still gated by somatostatin negative feedback, providing a built-in physiological safety mechanism not present with exogenous GH
  • Raun et al. (1998) found ipamorelin released GH with potency and efficacy similar to GHRP-6 in rats and swine, while GHRP-6 and GHRP-2 also raised ACTH and cortisol and ipamorelin did not
  • In rats dosed three times daily for 15 days, the GH response to a test dose of ipamorelin was marginally reduced while the response to GHRH was unchanged; no study of repeated dosing over weeks in people has been published

Ipamorelin Dosage

  • Standard anti-aging/wellness dose: 100–300 mcg subcutaneous injection, 1–3 times daily
  • Optimal timing: upon waking (fasted), post-workout, and 30 minutes before bed (for maximum GH pulse frequency)
  • Saturation dose: ~1 mcg/kg body weight per injection (100 mcg for 100 kg individual)
  • GH amplification stack: combine with 100 mcg CJC-1295 (no DAC) at each injection point for synergistic release
  • Body composition protocol: 200 mcg twice daily (AM fasted + pre-bed) for 12–16 weeks, then 4 weeks off
  • Sleep-focused protocol: 200–300 mcg 30 minutes before bedtime only
  • Must inject on an empty stomach — wait at least 2 hours after eating and 30 minutes before eating after injection
  • Cycle length: 8–16 weeks on, 4 weeks off (though some clinicians prescribe continuously with periodic blood work)
  • For women: same dosing applies — Ipamorelin is not sex-hormone-dependent
  • 5-days-on, 2-days-off protocol used by some practitioners to prevent desensitization while maintaining convenience
Ipamorelin dosage calculator: get your dose in syringe units →

Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.

Ipamorelin Side Effects & Safety

Known Side Effects

  • Mild head rush or transient lightheadedness immediately after injection (especially when fasted) — resolves within 5 minutes
  • Injection site reactions: minor redness or itching (common, transient)
  • Mild water retention during the first 1–2 weeks, typically subsiding as the body adapts
  • Occasional tingling or numbness in fingers/toes (transient paresthesia from GH effects)
  • Increased dream vividness and sleep depth — often considered a positive effect
  • Rare: mild nausea if injected immediately after eating (timing protocol compliance prevents this)
  • No significant appetite stimulation (unlike GHRP-6)
  • No meaningful cortisol or prolactin elevation in the animal studies that measured them; human hormone data are lacking

Safety Profile

Ipamorelin has arguably the best safety profile of any growth hormone secretagogue, which is why it has become the default recommendation for GH optimization. Its selectivity for GH release without cortisol, prolactin, or appetite disruption eliminates the most common GHRP side effects. The preservation of somatostatin negative feedback means Ipamorelin cannot drive GH to the dangerous supraphysiological levels possible with exogenous GH injections — providing an inherent safety ceiling. In the one controlled trial, in bowel resection patients, treatment-emergent adverse events occurred in 87.5% of the ipamorelin group and 94.8% of the placebo group, and FDA's review of that trial lists hypokalemia, insomnia, hyperglycemia, nausea, vomiting, abdominal distention and death among the reported events, with the relationship of the two deaths to ipamorelin unclear. Published human exposure runs to single infusions in volunteers and up to 7 days of twice-daily intravenous dosing, so there is no long-term human safety data. Standard monitoring includes IGF-1 levels (every 3–6 months), fasting glucose, and HbA1c (GH can mildly antagonize insulin action). Contraindications: active malignancy (GH/IGF-1 may promote tumor growth), uncontrolled diabetes, pituitary tumors, and pregnancy. Those with a strong family history of cancer should discuss IGF-1 optimization carefully with their physician. FDA's 2024 review concluded that compounding with ipamorelin may raise safety concerns and recommended against adding it to the list of bulk substances allowed in pharmacy compounding.

What to Expect

Week 1: Improved sleep quality is typically the first noticeable effect — deeper sleep, more vivid dreams, feeling more refreshed upon waking. This reflects enhanced nocturnal GH pulses during slow-wave sleep. Mild water retention possible. Week 2–3: Sleep benefits consolidate. Recovery from exercise improves noticeably — less soreness, faster return to baseline. Skin begins to appear more hydrated and 'fuller.' Subtle improvements in mood and energy. Weeks 4–6: Body composition changes become measurable — reduced subcutaneous fat, improved muscle tone. Hair and nail growth accelerates. Skin quality continues to improve (fine lines appear softer, complexion brighter). Joint comfort may improve as synovial fluid and cartilage benefit from GH effects. Weeks 7–12: Peak protocol benefits. Measurable fat loss (especially truncal/visceral) and lean mass improvements are evident. IGF-1 blood levels typically elevated 30–60% above baseline. Energy and exercise capacity improved. Skin looks noticeably more youthful. Weeks 12–16: Benefits plateau at maximum. After cycling off, improvements in body composition, skin quality, and sleep partially persist for 4–8 weeks before gradually returning toward baseline. Many users adopt a long-term intermittent strategy: 12 weeks on, 4 weeks off, repeating indefinitely.

Common Stacks

Storage & Handling

Store lyophilized Ipamorelin at 2–8°C for up to 12 months or -20°C for up to 24 months. Reconstitute with bacteriostatic water — typically 1–2 mL per vial (adjust based on vial size for convenient dosing). Once reconstituted, refrigerate at 2–8°C and use within 4–6 weeks. Ipamorelin is a relatively stable peptide but should be protected from light and excessive heat. Do not shake — gently swirl to dissolve. Clear, colorless solution; discard if cloudy or discolored.

Pricing & Available Variants

$30 – $59price range
5mg10mg

Prices sourced from peptides.gg marketplace. Prices may vary.

References

  1. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998.
  2. Beck DE, Sweeney WB, McCarter MD. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014.
  3. Gobburu JV, Agersø H, Jusko WJ, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999.
  4. FDA Briefing Document, Pharmacy Compounding Advisory Committee: evaluation of ipamorelin (free base) and ipamorelin acetate for the 503A Bulk Drug Substances List. U.S. Food and Drug Administration. 2024.
  5. Svensson J, Lall S, Dickson SL, et al. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000.
  6. Johansen PB, Nowak J, Skjaerbaek C, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999.
  7. Veldhuis JD, Bowers CY. Determinants of GH-releasing hormone and GH-releasing peptide synergy in men. Am J Physiol Endocrinol Metab. 2009.
  8. Jiménez-Reina L, Cañete R, de la Torre MJ, et al. Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro. Histol Histopathol. 2002.
  9. Venkova K, Mann W, Nelson R, et al. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther. 2009.
Deep dive

Ipamorelin Guide

Read the full guide

Related Peptides

Track Ipamorelin in Your Protocol

Log your Ipamorelin doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.

Start Tracking Free